SOURCE: MMIT Analytics, as of 5/14/19
To be a Medicare Agent's source of information on topics affecting the agent and their business, and most importantly, their clientele, is the intention of this site. Sourced from various means rooted in the health insurance industry - insurance carriers, governmental agencies, and industry news agencies, this is aimed as a resource of varying viewpoints to spark critical thought and discussion. We welcome your contributions.
Wednesday, May 15, 2019
Teva's generic to Gilead's blockbuster AIDS treatment and prevention drug, Truvada, could...
...launch as early as 2020,
according to a newly filed agreement between the two companies. The generic
copy originally wasn't expected to launch until 2021. In the pharmacy benefit,
Truvada currently holds preferred status for 64% of covered lives. The
Department of Justice is currently investigating the legitimacy of Gilead's
patent for Truvada, but Gilead said its new agreement is not related to that
activity.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment